Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,

Intervention/treatment:
XTANDI (ENZALUTAMIDE, MDV3100)
Medical condition:
PROSTATE CANCER
Protocol code:
MDV3100-14
Control number:
166719
Status:
Closed
Approved:
August 15, 2013
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02003924
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: MALE
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA INC

Locations

Alberta

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2

British Columbia

Vancouver Prostate Centre
Vancouver, British Columbia, V5Z 1M9

Manitoba

Manitoba Prostate Centre CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9

Nova Scotia

NS Health Authority, Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9

Ontario

London Regional Cancer Program - Victoria Hospital, London Health Sciences Centre(LHSC)
London, Ontario, N6A 4L6
McMaster Institute of Urology @ St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6
SunnyBrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
The Male/Female Health and Research Centre
Barrie, Ontario, L4M 7G1
University Health Network- Princess Margaret Cancer Centre
Toronto, Ontario, M5G2M9
Urology Associates / Urologic Medical Research
Kitchener, Ontario, N2N 2B9
Urology Reasearch - Victoria Hospital, London Health Sciences Centre(LHSC)
London, Ontario, N6A 5W9

Quebec

Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 3E4
CHU de Quebec
Québec, Quebec, G1R 2J6
McGill University Health Centre
Montreal, Quebec, H4A 3J1
Urology South Shore Research
Greenfield Park, Quebec, J4V 2H3

Results

See the results from the trial NCT02003924. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?